Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 51% Improvement Relative Risk ICU admission 72% c19early.org/d Argano et al. Vitamin D for COVID-19 META ANALYSIS Favors vitamin D Favors control
Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis
Argano et al., Pharmaceuticals, doi:10.3390/ph16010130
Argano et al., Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and.., Pharmaceuticals, doi:10.3390/ph16010130
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Meta analysis and trial sequential analysis of 5 vitamin D RCTs, showing significantly lower mortality and ICU admission with treatment. Only a small subset of the 25 RCTs are included. Note that [Nogués] uses randomization by ward, was censored by the Lancet, and was later reworded as an observational trial. The groups are relatively well matched, with only baseline vitamin D levels (median 13 vs. 12) showing a significant difference (matching is better than many trials that use the term randomized for their randomization without censorship). For more details see [Nogués].
Currently there are 104 vitamin D studies and meta analysis shows:
OutcomeImprovement
Mortality37% lower [28‑44%]
Ventilation26% lower [-2‑46%]
ICU admission50% lower [33‑62%]
Hospitalization20% lower [8‑31%]
Cases12% fewer [3‑21%]
risk of death, 51.0% lower, OR 0.49, p < 0.001, RR approximated with OR.
risk of ICU admission, 72.0% lower, OR 0.28, p < 0.001, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Argano et al., 16 Jan 2023, peer-reviewed, 6 authors.
Contact: chargano@yahoo.it (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: pharmaceuticals Systematic Review Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis Christiano Argano 1, * , Raffaella Mallaci Bocchio 1 , Giuseppe Natoli 1 , Salvatore Scibetta 1 , Marika Lo Monaco 1,2 and Salvatore Corrao 1,2 1 2 * Citation: Argano, C.; Mallaci Bocchio, R.; Natoli, G.; Scibetta, S.; Lo Monaco, M.; Corrao, S. Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis. Pharmaceuticals 2023, 16, 130. https://doi.org/10.3390/ ph16010130 Academic Editor: Julia O. Fedotova Internal Medicine Department iGR, National Relevance Hospital Trust, ARNAS Civico, Di Cristina e Benfratelli, 90127 Palermo, Italy Dipartimento di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, PROMISE, University of Palermo, 90127 Palermo, Italy Correspondence: chargano@yahoo.it; Tel.: +39-091-655-2065; Fax: +39-091-666-3167 Abstract: Background: The COVID-19 pandemic represents one of the world’s most important challenges for global public healthcare. Various studies have found an association between severe vitamin D deficiency and COVID-19-related outcomes. Vitamin D plays a crucial role in immune function and inflammation. Recent data have suggested a protective role of vitamin D in COVID-19related health outcomes. The purpose of this meta-analysis and trial sequential analysis (TSA) was to better explain the strength of the association between the protective role of vitamin D supplementation and the risk of mortality and admission to intensive care units (ICUs) in patients with COVID-19. Methods: We searched four databases on 20 September 2022. Two reviewers screened the randomized clinical trials (RCTs) and assessed the risk of bias, independently and in duplicate. The pre-specified outcomes of interest were mortality and ICU admission. Results: We identified 78 bibliographic citations. After the reviewers’ screening, only five RCTs were found to be suitable for our analysis. We performed meta-analyses and then TSAs. Vitamin D administration results in a decreased risk of death and ICU admission (standardized mean difference (95% CI): 0.49 (0.34–0.72) and 0.28 (0.20–0.39), respectively). The TSA of the protective role of vitamin D and ICU admission showed that, since the pooling of the studies reached a definite sample size, the positive association is conclusive. The TSA of the protective role of vitamin D in mortality risk showed that the z-curve was inside the alpha boundaries, indicating that the positive results need further studies. Discussion: The results of the meta-analyses and respective TSAs suggest a definitive association between the protective role of vitamin D and ICU hospitalization. Keywords: vitamin D; COVID-19; ICU hospitalization; mortality; meta-analysis; trial sequential analysis Received: 23 November 2022 Revised: 27 December 2022 Accepted: 31 December 2022 Published: 16 January 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit